Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

赛马鲁肽 医学 荟萃分析 安慰剂 内科学 2型糖尿病 随机对照试验 置信区间 不利影响 糖尿病 内分泌学 利拉鲁肽 病理 替代医学
作者
Thomas Karagiannis,Konstantinos Malandris,Ioannis Avgerinos,Athina Stamati,Panagiota Kakotrichi,Aris Liakos,Despoina Vasilakou,Nikolaos Kakaletsis,Απόστολος Τσάπας,Eleni Bekiari
出处
期刊:Diabetologia [Springer Science+Business Media]
卷期号:67 (7): 1206-1222 被引量:19
标识
DOI:10.1007/s00125-024-06144-1
摘要

Abstract Aims/hypothesis We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA 1c and body weight from baseline. Secondary outcomes were achievement of HbA 1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. Results A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [−1.39%]) and semaglutide 0.5 mg (−12.00 mmol/mol [−1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. Conclusions/interpretation Our data show that s.c. tirzepatide had a more pronounced effect on HbA 1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. Registration PROSPERO registration no. CRD42022382594 Graphical Abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夜曦完成签到 ,获得积分0
1秒前
DELI完成签到 ,获得积分10
3秒前
白智妍完成签到,获得积分10
3秒前
3秒前
4秒前
Snail发布了新的文献求助10
8秒前
俭朴的世界完成签到 ,获得积分10
8秒前
十七完成签到 ,获得积分10
9秒前
李梦媛完成签到 ,获得积分10
9秒前
小七完成签到,获得积分10
10秒前
leapper完成签到 ,获得积分10
10秒前
光亮的绮晴完成签到 ,获得积分10
10秒前
赘婿应助大橙子采纳,获得10
16秒前
sfsfes应助ABC采纳,获得10
16秒前
SciGPT应助强公子采纳,获得10
16秒前
RXY完成签到,获得积分10
17秒前
量子星尘发布了新的文献求助10
19秒前
明明完成签到,获得积分10
20秒前
求知的周完成签到,获得积分10
20秒前
21秒前
柒柒球完成签到,获得积分10
21秒前
赵田完成签到 ,获得积分10
22秒前
22秒前
长安完成签到,获得积分10
26秒前
大橙子发布了新的文献求助10
27秒前
在水一方应助Herisland采纳,获得10
29秒前
笨笨小刺猬完成签到,获得积分10
31秒前
31秒前
科研小达人完成签到,获得积分10
34秒前
追寻凌青完成签到,获得积分10
36秒前
渡劫完成签到,获得积分10
37秒前
丫丫完成签到 ,获得积分10
37秒前
lxy发布了新的文献求助10
38秒前
bono完成签到 ,获得积分10
41秒前
DentistRui完成签到,获得积分10
41秒前
43秒前
laber应助忧伤的步美采纳,获得50
46秒前
淡淡月饼发布了新的文献求助20
47秒前
茶茶应助虞无声采纳,获得50
47秒前
大橙子发布了新的文献求助10
49秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022